Head and neck squamous cell carcinomas (HNSCC) are characterized by upregulation of the epidermal growth factor receptor (EGFR), where EGFR serves as a potential therapeutic target. We previously reported that a gastrin-releasing peptide/gastrin-releasing peptide receptor (GRP/GRPR) autocrine growth pathway is activated early in HNSCC carcinogenesis. In the present study, we examined the mechanism of EGFR activation by GRP/GRPR in HNSCC proliferation. In HNSCC cells that express elevated levels of both GRPR and EGFR, we found that GRP induced rapid phosphorylation of EGFR as well as p44/42-MAPK activation. Using several EGFR-specific tyrosine kinase inhibitors and cells derived from EGFR knockout mice, we demonstrated that GRPinduced p44/42-MAPK activation was dependent upon EGFR activation. Further investigation demonstrated that cleavage of transforming growth factor-alpha (TGF-a) by matrix metalloproteinases mediated GRP-induced MAPK activation. In addition, HNSCC proliferation stimulated by GRP was eliminated upon specific inhibition of EGFR or MEK, and GRP failed to stimulate proliferation in EGFR-deficient cells. These results imply that the mitogenic effects of GRP in HNSCC are mediated by extracellular release of TGF-a and require the activation of an EGFR-dependent MEK/MAPK-dependent pathway.
Introduction
Gastrin-releasing peptide (GRP) is the mammalian counterpart of an amphibian tetradecapeptide known as bombesin (Anastasi et al., 1971) . GRP, and other mammalian bombesin-like peptides (BLPs) such as neuromedin B, regulate a wide spectrum of physiological effects, including smooth muscle contraction, hormone secretion, metabolism, homeostasis and mitogenesis (Lebacq-Verheyden et al., 1990) . The effects of GRP are primarily mediated through binding to its receptor, GRPR. GRPR is a G-protein-coupled receptor (GPCR), originally isolated from a small cell lung cancer cell line (Corjay et al., 1991) . Other BLPs exert their effects via neuromedin B receptor (NMBR) or bombesin receptor subtypes 3 and 4 (Corjay et al., 1991; Wada et al., 1991; Fathi et al., 1993; Nagalla et al., 1995) .
Cumulative evidence supports an important role for GRP/GRPR and other BLPs in carcinogenesis. Overexpression of GRPR has been shown to promote proliferation in Balb/3T3 and Rat-1 fibroblasts (Lach et al., 1995; Feldman et al., 1996) . Upregulation of GRP/GRPR, or BLP receptors and their ligands have been reported in various cancers including carcinomas of the lung (both small cell lung carcinoma and nonsmall cell lung carcinoma), prostate, colon, kidney, breast and ovary, as well as glioblastoma (Halmos et al., 1995; Sharif et al., 1997; Siegfried et al., 1999; Carroll et al., 2000; Pansky et al., 2000; Rounseville & Davis, 2000; Sun et al., 2000a, b) . GRP/GRPR has been shown to contribute to lung carcinogenesis by autocrine growth stimulation. Both SCLC and NSCLC cells produce and secrete GRP, resulting in tumor cell proliferation (Carney et al., 1987; Siegfried et al., 1999) . GRP has been reported to stimulate DNA synthesis in a glioblastoma cell line, U-373MG (Sharif et al., 1997) . In addition, GRP has been demonstrated to enhance tumor cell motility as well as invasiveness in prostate cancer cell lines (Nagakawa et al., 2000 (Nagakawa et al., , 2001 .
We recently reported an autocrine pathway involving GRP/GRPR in head and neck squamous cell carcinogenesis (Lango et al., 2002) . Elevated expression levels of GRPR were detected in histological normal mucosa as well as tumors harvested from HNSCC patients compared with levels in mucosa from control patients without cancer. The treatment of HNSCC cells with a neutralizing monoclonal antibody directed against GRP resulted in growth inhibition both in vitro and in vivo. Expression levels of GRPR in the primary HNSCC tumor were associated with nodal metastasis and extracapsular invasion, implicating GRPR in tumor progression (Lango et al., 2002) . However, the detailed molecular mechanisms involved in GRP/GRPRmediated tumor growth are incompletely understood.
More than 95% of HNSCC tumors demonstrate epidermal growth factor receptor (EGFR) overexpression. Moreover, the levels of EGFR expression in the primary HNSCC tumor are highly significant and independent predictors of decreased survival (Rubin Grandis et al., 1998) . EGFR mitogenic signaling usually occurs following receptor activation by direct ligand binding. However, ligand-independent receptor activation has also been reported (Adelsman et al., 1996; Boerner et al., 2001) . Cumulative evidence suggests a new and potentially central role for EGFR as a convergence point for input from a diverse number of signaling pathways, including that of several GPCRs and receptor tyrosine kinases (Gschwind et al., 2001) . Transactivation of EGFR by GPCRs has been demonstrated in many noncancer systems, including vascular smooth muscle (by angiotensin II), primary astrocytes (by thrombin), keratinocytes (Daub et al., 1997) , NIH 3T3 fibroblasts (by LPA), Swiss 3T3 fibroblasts (by LPA, bradykinin and bombesin), Rat-1 cells (by endothelin-1, LPA, thrombin and bombesin) and COS-7 cells (by bombesin, carbachol and LPA). However, little is known about the contribution of GPCR-mediated EGFR transactivation to carcinogenesis and tumor growth (Gschwind et al., 2001) . EGFR transactivation by GPCRs has been observed in ovarian cancer cells SK-OV-3 by interleukin-8 (Venkatakrishnan et al., 2000) , astroglioma cells U-3T3 MG by substance P (Castagliuolo et al., 2000) and PC-3 prostate cancer cells by bombesin (Prenzel et al., 1999) .
Ligand binding to GRPR or bombesin receptors results in the activation of heterotrimeric G proteins, such as Gaq, Gbg and the G 12 family (Buhl et al., 1995; Hellmich et al., 1997) . Activation of these small G proteins then leads to stimulation of multiple signaling pathways such as Ras/Raf/MAPK pathway, phospholipase C-b (PLC-b), protein kinase C (PKC) as well as phosphorylation of focal adhesion kinase and paxillin (Charlesworth et al., 1996) . However, little is known about the relative importance of these different signaling pathways in GRP/GRPR-mediated cancer growth.
In this study, we examined the mechanism of GRPmediated growth stimulation of HNSCC cells. Since both GRPR and EGFR have been shown to be upregulated early in HNSCC carcinogenesis, we hypothesized that GRP stimulation would result in the activation of EGFR in HNSCC. Our results support a central role for EGFR in mediating the growth stimulatory effects of GRP in HNSCC via MAPK activation. Using both an HNSCC model and EGFR knockout cells, we demonstrated, for the first time, that GRP-induced cancer cell proliferation is dependent upon EGFR signaling.
Results

GRP-induced tyrosine phosphorylation of EGFR
We have previously shown that a GRP/GRPR autocrine pathway is activated early in HNSCC carcinogenesis (Lango et al., 2002) . Moreover, we also demonstrated that the addition of recombinant GRP resulted in growth stimulation in various HNSCC cell lines, including 1483 (Lango et al., 2002) . To determine if exogenous GRPR ligand could induce the activation of EGFR in HNSCC, 1483 cells were treated with GRP after 72 h of serum starvation. At 2, 10 and 60 min after GRP addition, cells were harvested for immunprecipitation to detect EGFR activation. GRP caused an immediate increase in tyrosine phosphorylation of EGFR. As shown in Figure 1a , EGFR tyrosine phosphorylation was elevated on an average of 1.6-fold by 2 min. Moreover, the specificity of EGFR activation by GRP was demonstrated by pretreatment with an EGFR-specific tyrosine kinase inhibitor, PD153035, which abrogated GRP-induced EGFR activation (data not shown). Activation of EGFR by GRP was observed in two other HNSCC cell lines, UM-22B and UP-CI:SCC103 (data not shown). These results suggest that V e h i c l e c o n t r o l E G F 1 0 m i n G R P 2 m i n G R P 1 0 m i n G R P 6 0 m i n Representative HNSCC cells (1483), were treated with 400 nm GRP in serum-free DMEM. At 2, 10 and 60 min after the addition of GRP, cell lysates were harvested for immunoprecipitation with an EGFR monoclonal antibody, and subsequent Western blotting with antiphosphotyrosine antibody (PY99). The blot was stripped and reprobed with anti-EGFR antibody to demonstrate equal expression levels of EGFR and equal loading of protein lysates. The control lane represents the basal phosphorylation level of EGFR in untreated cells. EGF stimulation (10 ng/ml) was performed as a positive control for EGFR phosphorylation.
Cumulative results from three independent experiments are shown activation of GRPR by GRP results in the phosphorylation of EGFR in HNSCC cells.
Phosphorylation of p44/42-MAPK by GRP
GPCR-3 mediated EGFR transactivation in other systems has been shown to result in p44/42-MAPK activation (Gschwind et al., 2001) . To examine the potential activation of p44/42-MAPK by GRP in HNSCC, exogenous GRP was added to HNSCC cells and the phosphorylation levels of p44/42-MAPK were determined. The addition of GRP to HNSCC cells resulted in immediate activation of p44/42-MAPK. As early as 10 min after the addition of exogenous GRP, phosphorylation of p44/42-MAPK was increased by an average of 2.1-fold (Figure 2a ). The experiment was repeated using a lower, more physiologic concentration (10 nm) to ensure that GRP stimulates MAPK activation under conditions that reflect the tumor cell microenvironment more closely ( Figure 2b ). The specificity of the GRP-mediated phosphorylation of p44/42-MAPK was demonstrated using the MEK-specific inhibitor, U0126. In the presence of the MEK inhibitor, GRP-induced phosphorylation of p44/42-MAPK was completely blocked (Figure 2c ). This demonstrates that GRP stimulates p44/42-MAPK primarily through the MEK/MAPK pathway.
EGFR mediates GRP-induced p44/42-MAPK activation
GRP has been reported to induce p44/42-MAPK activation via either an EGFR-dependent mechanism or an EGFR-independent mechanism in Rat-1 and Swiss 3T3 fibroblasts, respectively (Santiskulvong et al., 2001) . Therefore, we examined if EGFR activation mediated GRP-induced activation of p44/42-MAPK in HNSCC cells. HNSCC (1483) cells were preincubated with either of two EGFR-specific tyrosine kinase inhibitors, PD153035 or AG-1478 followed by treatment with GRP and determination of MAPK expression/activation. Treatment of HNSCC cells with EGFRspecific tyrosine kinase inhibitors at these concentrations has been previously shown to specifically inhibit EGFR phosphorylation (Grandis et al., 1997) . As shown in Figure 3a , EGFR tyrosine kinase inhibition (using PD153035 and AG-1478, respectively) resulted in lower levels of GRP-induced p44/42-MAPK phosphorylation compared to GRP treatment alone. Moderate activation of MAPK by GRP in the presence of EGFR inhibition suggests that EGFR-independent mechanisms of MAPK activation by GRP are also possible. Treatment with a control inhibitor that does not block EGFR tyrosine kinase activity (AG-9) did not mitigate GRP-induced MAPK activation (Figure 3b ). To demonstrate the specificity of the observed effects, the experiment was repeated using an EGFR-independent stimulus, hepatocyte growth factor (HGF). As shown in Figure 3c , the treatment of HNSCC cells with HGF (50 ng/ml) resulted in MAPK phosphorylation that was not abrogated by pretreatment with an EGFRspecific tyrosine kinase inhibitor. To verify that EGFR was required for activation of MAPK by GRP, we repeated the experiment using cells derived from EGFR knockout mice and their wild-type littermates. Both wild-type and EGFR knockout fibroblasts were found to express GRPR as determined by immunoblotting (data not shown). Western blotting demonstrated the expression of EGFR in the cells derived from the wild-type mice and absence of EGFR expression in corresponding cells from the knockout mice (data not shown). As shown in Figure 4 , EGF or GRP treatment induced rapid MAPK activation (average 2.3-and 1.7-fold, respectively) as demonstrated by phosphorylated p44/42 expression, in cells derived from wild-type mice. In contrast, corresponding to EGFR knockout cells, GRP stimulation failed to result in 
TGF-a mediates GRP-induced EGFR activation
Activation of EGFR by GPCRs has been shown to involve both intracellular and/or extracellular pathways. Extracellular processing of the EGFR ligand, proheparin-binding epidermal growth factor (pro-HB-EGF) has been primarily implicated in EGFR activation by GPCRs (Prenzel et al., 1999) . A mutated form of diphtheria toxin, CRM197, has been shown to bind specifically to HB-EGF and inhibit its mitogenic activity (Mitamura et al., 1995) . Prenzel et al. reported that CRM197 pretreatment could completely inhibit EGFR activation induced by GPCRs in COS-7 cells (Prenzel et al., 1999) . To examine the role of HB-EGF in EGFR activation in HNSCC, cells were pretreated with CRM197 (1 mg/ml) or an HB-EGF neutralizing antibody prior to GRP stimulation. As shown in Figure 5a , CRM197 did not abrogate EGFR activation induced by GRP in all three HNSCC cell lines examined, indicating that proHB-EGF processing is not responsible for GRPmediated EGFR activation in HNSCC (Figure5a and data not shown).
We have previously reported that TGF-a is the primary autocrine EGFR ligand in HNSCC. We therefore hypothesized that GRP-induced EGFR activation in HNSCC was mediated by TGF-a binding to EGFR.
To test this hypothesis, we examined GRP-stimulated EGFR phosphorylation and MAPK activation in the presence of a TGF-a neutralizing antibody or an EGFR blocking antibody (M225). As shown in Figure 5b , GRP-mediated MAPK activation was abrogated upon TGF-a blockade or inhibition of EGFR ligand binding. ProTGF-a exists as a membrane-anchored protein, that when cleaved by proteases, is released and bound by the EGFR extracellular ligand-binding domain. To determine whether GRP could stimulate TGF-a release, TGF-a was measured in HNSCC cell line supernatants in the presence of GRP and a matrix metalloproteinase inhibitor. As shown in Figure 5c , GRP induced TGF-a secretion, an effect that was blocked by the MMP inhibitor, Marimastat. Further investigation demonstrated that GRP-induced EGFR phosphorylation and MAPK activation could be nearly completely blocked by either of two MMP inhibitors (Figure 5d ). The inhibition of MAPK activation by the MMP inhibitors in both the presence and absence of exogenous GRP suggests that the metalloprotease inhibitors are also interfering with autocrine stimulation of GRPR. In addition, there may be other MAPK activation pathways in these cells that are blocked by MMP inhibitors. Thus, while MMP inhibitors likely also block other pathways, MMP cleavage of TGF-a appears to mediate the activation of EGFR by GRP in HNSCC cells.
MEK/MAPK pathway is the major pathway mediating mitogenic effects of GRP
Previously, we reported that the addition of exogenous GRP resulted in dose-dependent growth stimulation of HNSCC cells (Lango et al., 2002) . Since exogenous GRP also resulted in strong activation of p44/42-MAPK in HNSCC cells, we examined the role of MEK/MAPK in mediating the growth stimulatory effects of GRP. HNSCC cells were treated with different concentrations of GRP in the presence or absence of the MEK inhibitor, U0126 or DMSO control. As shown in Figure 6 , increasing concentrations of GRP (5-200 nm) resulted in a dose-dependent growth stimulation of HNSCC cells at 72 h. At all concentrations of GRP tested, the MEK inhibitor resulted in complete abrogation of GRP-induced proliferation. Our results strongly suggest that the growth stimulatory effects of GRP on HNSCC cells are primarily mediated through activation of the MEK/MAPK pathway.
Inhibition of GRP-mediated growth stimulation by EGFR blockade
To determine the role of EGFR in the growth stimulatory effects of GRP on HNSCC, several HNSCC cell lines were treated with different concentrations of GRP in the presence or absence of an EGFR-specific tyrosine kinase inhibitor (PD153035). At all concentrations of GRP, growth stimulation was prevented by EGFR blockade (Figure 7a-c) . Similar effects were observed with another EGFR-specific tyrosine kinase inhibitor, AG-1478 (Figure 7d) . Compared with the DMSO vehicle control, AG-1478 resulted in significant inhibition (90.5711.65% inhibition, P ¼ 0.0068) of GRP-induced proliferation; while the control compound AG-9 resulted in no growth inhibition (P ¼ 0.4483) (Figure 7e ). In addition to the use of pharmacological EGFR inhibitors in HNSCC cells, we examined the requirement of EGFR for GRP-induced mitogenesis in murine EGFR knockout cells. As shown in Figure 7f , treatment of cells derived from EGFR knockout mice with GRP or EGF failed to result in proliferation. In contrast, treatment of cells derived from their EGFR wild-type littermates with either ligand modestly stimulated cell growth. In addition, the treatment of EGFR knockout or wild-type cells with serum stimulated growth, demonstrating that these cells can be stimulated to proliferate in vitro. These results strongly suggest that EGFR tyrosine kinase activity primarily mediates the growth stimulatory effects of GRP in HNSCC.
Discussion
We previously reported upregulation of GRP/GRPR in HNSCC cell lines and tissues, implicating a GRP/ GRPR autocrine growth pathway in HNSCC carcinogenesis (Lango et al., 2002) . A similar GRP/GRPR autocrine pathway has been demonstrated to be important in (1483) were pretreated with 1 mg/ml of CRM197 or HB-EGF neutralization antibody (5 ng/ml) for 2 h before the addition of GRP (400 nm) in serum-free DMEM. At 10 and 30 min after the addition of GRP, cell lysates were then harvested for immunoprecipitation with an EGFR monoclonal antibody, and subsequent Western blotting with antiphosphoyrosine antibody (PY99). The blot was stripped and reprobed with anti-EGFR antibody to show equal expression of EGFR and loading of protein lysates. EGF stimulation (10 ng/ml) was performed as a positive control for EGFR phosphorylation. The control lane represents the basal phosphorylation level of EGFR in vehicle-treated cells. Cumulative results are shown from two independent experiments. (b) TGF-a is responsible for mediating GRPmediated EGFR activation. HNSCC cells were treated with TGF-a neutralizing antibody (7 mg/ml) or an EGFR blocking antibody (M225) for 24 h prior to GRP stimulation (400 nm, 10 min), or antibody alone, followed by immunoblotting for MAPK and phosphorylated MAPK. (c) TGF-a is released into the supernatant by GRP stimulation. HNSCC cells were serum starved for 72 h and pretreated with Marimastat (20 mm) for 2 h prior to treatment with GRP (400 nm) for 10 min. Cell line supernatants were harvested for analysis using a TGF-a ELISA assay. (d) MMP inhibition blocks GRP-mediated EGFR activation. Cellular MMPs were inhibited by preincubation for 2 h with either Marimastat (20 mm) or GM6001 (25 nm) followed by GRP stimulation (400 nm). Cells were harvested after 10 min for coimmunoprecipitation to determine EGFR phosphorylation and immunoblotting to determine the expression of total EGFR, MAPK and phosphorylated MAPK. Cumulative results are shown from three independent experiments the mitogenesis of SCLC and NSCLC (Carney et al., 1987; Siegfried et al., 1999) . More than 50% of SCLC and NSCLC cell lines express elevated levels of GRP or GRPR (Sorenson et al., 1982; Alexander et al., 1988; Siegfried et al., 1998; ) . Sun et al. reported that approximately 60% of primary prostate cancer cells express GRPR (Sun et al., 2000a) . In vitro and in vivo ablation of the GRP/GRPR autocrine pathway using a GRP neutralizing antibody or bombesin analogs resulted in the inhibition of tumor growth in preclinical models of SCLC, NSCLC and prostate cancer in addition to HNSCC (Kelley et al., 1997; Siegfried et al., 1999; Plonowski et al., 2000) . The therapeutic efficacy of the GRP neutralizing antibody (2A11) in SCLC is under clinical investigation (Kelley et al., 1997; Chaudhry et al., 1999) . However, the detailed molecular mechanisms involved in GRP/GRPR-mediated tumor growth have not been incompletely understood. In the present investigation, we attempted to elucidate the signaling pathways underlying GRP-induced mitogenesis in HNSCC. For the first time, we demonstrated that the stimulatory effects of GRP on cancer growth require an EGFR-dependent MEK/MAPK-dependent activation pathway that is triggered by extracellular release of TGF-a. These results suggest that the EGFR-dependent growth stimulatory action of GRP may mediate tumor growth pathways in a variety of cancers including HNSCC, which express EGFR. GPCRs transmit their signals through activation of small G proteins, such as Ga and Gbg subunits. These small G proteins, in turn, activate various signaling pathways including Ras/Raf/MAPK, PLC and PKC pathways. Several studies have demonstrated cross-talk between various GPCRs and receptor tyrosine kinases, including EGFR (Gschwind et al., 2001 ). EGFR appears to be a central convergence point for various GPCR signaling pathways, including endothelin-1, LPA, thrombin, angiotensin II, bradykinin, carbachol, substance P, interleukin-8 and bombesin, in addition to GRP (Gschwind et al., 2001) . GPCRs can also activate receptor tyrosine kinases other than EGFR. PDGFR transactivation has been demonstrated in COS-7 cells and vascular smooth muscle (by LPA and angiotensin II, respectively) (Linseman et al., 1995; Herrlich et al., 1998; Heeneman et al., 2000) , and IGF1R transactivation was reported in primary rat smooth muscle cells by thrombin stimulation (Rao et al., 1995) . Earlier work on the mitogenic response in quiescent murine fibroblasts (Swiss 3T3 cells) demonstrated that certain growth factors can confer a ''complete'' mitogenic response, while others are dependent upon the presence of other factors to activate complementary pathways (Rozengurt, 1986) . Bombesin, an analog of GRP that acts through the GRPR, was found to stimulate mitogenesis in the absence of serum or any other added growth factors (Rozengurt and Sinnett-Smith, 1998; Rozengurt, 1986) . Neither agents that increase cyclic AMP nor those that activate protein kinase C (PKC) enhanced the mitogenic effects of bombesin in Swiss 3T3 cells (Rozengurt, 1986; Rozengurt and Sinnett-Smith, 1983) . In contrast, EGF required the presence of bombesin, insulin, or an agent that stimulates PKC to confer a mitogenic response. These earlier observations, in light of our results, suggest that GRP, an analog of bombesin, may act as a 'complete' mitogenic factor because it stimulates complementary pathways that are required for a maximal mitogenic response. One of these critical pathways is the activation of EGFR. However, the EGFR pathway by itself is probably not sufficient to bring about maximal growth stimulation, since in serum-free conditions, EGF alone is usually not mitogenic (Rozengurt, 1986) .
The widespread overexpression of EGFR in most epithelial malignancies and its important role in directly mediating tumor proliferation underscores the importance of developing a better understanding of the role of EGFR in relaying signals from GPCR pathways. MAPK activation has been previously implicated in mediating GPCR/EGFR signaling pathways in fibroblasts. It is generally believed that MAPK activation mediated through GPCR/EGFR drives cellular proliferation (Sharif et al., 1997; Castagliuolo et al., 2000) . However, Santiskulvong et al. showed that an EGFRdependent, but MAPK-independent pathway could also mediate the mitogenic effects of GPCR activation (Santiskulvong et al., 2001) .
GPCRs have been shown to induce EGFR transactivation through a combination of intracellular and extracellular events depending on the cell type and activating ligand (Prenzel et al., 1999) . Ligand binding to GPCRs results in the stimulation of Ca 2 þ -and PKCdependent processes, leading to the activation of metalloproteinases. Activated metalloproteinases can cleave and process transmembrane EGF-like growth factor precursors, resulting in the release of EGFR ligands from the cell membrane and ultimately, EGFR activation. Inhibition of the cleavage of EGFR ligand, proHB-EGF, by a mutant diphtheria toxin, CRM197, has been shown to reduce GPCR-mediated EGFR transactivation in COS-7 cells. However, in all three HNSCC lines tested, CRM197 treatment did not abrogate GRPinduced EGFR phosphorylation. We have previously shown that HNSCC cells express high levels of TGF-a resulting in autocrine stimulation of EGFR (Grandis et al., 1997) . In the present study, we demonstrate that GRP induces EGFR activation, at least in part, via TGF-a cleavage. Our findings corroborate a recent report in nontransformed colonic epithelial cells, where the GPCR ligand carbachol was shown to activate EGFR by the release of TGF-a (McCole et al., 2002) . -1478) . (e) In contrast, the treatment of 1483 cells with a control inhibitor (250 nm of AG-9) did not abrogate GRP-induced mitogenesis. (f) Cells derived from EGFR knockout mice or their wild-type littermates were treated with GRP (400 nm) or EGF (l0 ng/ml) or serum (20%) for 2 days followed by growth determinations using vital dye exclusion GRP serves as a mitogenic factor for fibroblasts and some cancer cells, including SCLC, NSCLC, HNSCC and glioblastoma (Carney et al., 1987; Siegfried et al., 1999; Nagakawa et al., 2000) . However, the potential role of EGFR in mediating the effects of GRP has not been studied previously. Indirect evidence suggests the potential involvement of EGFR in GRP or BLP signaling. In several in vivo tumor models (including SCLC and estrogen-dependent and estrogen-independent MTX mouse mammary cancers), treatment with a synthetic bombesin/GRP antagonist, RC-3095, resulted in the downregulation of EGFR mRNA expression levels (Pinski et al., 1994; Halmos and Schally, 1997; Szepeshazi et al., 1997; Koppan et al., 1998) . Moreover, Liebow et al. showed that bombesin and EGF seemed to promote phosphorylation of similar substrates (Liebow et al., 1994) . Bombesin, which binds with high affinities to multiple BLP receptors, including NMBR and bombesin receptor subtype 4 (Akeson et al., 1997) , has been shown to transactivate EGFR in the PC-1 prostate cancer cell line (Prenzel et al., 1999) . However, the biologic consequences of bombesin-induced EGFR trans;-activation in prostate cancer were not investigated. In the present study, we demonstrated that GRP-induced HNSCC tumor growth requires EGFR activation.
MAPK activation by GPCR-mediated EGFR transactivation in nontransformed cells has been reported previously. In noncancer cell lines (rodent Rat-1 and Swiss 3T3 fibroblasts), bombesin has also been reported to induce EGFR-dependent DNA synthesis (Santiskulvong et al., 2001) . However, bombesin-or bradykinininduced EGFR-dependent DNA synthesis was believed to be MAPK-independent (Santiskulvong et al., 2001) . In contrast, we demonstrated that an EGFR-dependent and MEK/MAPK-dependent pathway was primarily responsible for the growth stimulatory effects of GRP on HNSCC cells. While all the potential pathways induced by GRP are likely stimulated at higher concentrations of ligand, a dependence on EGFR is still observed. These results suggest that GRP and bombesin may have different mechanisms of actions on different cells. Alternative EGFR mitogenic pathways other than MAPK, may also be responsible for the growth stimulatory effects of different BLPs on various cell types.
In addition to MAPK activation, cross-talk between GPCRs and EGFR has been shown to result in the modulation of immediate early gene transcription, DNA synthesis, potassium ion channel activity, chloride ion secretion and or stress fiber formation in various systems (Gschwind et al., 2001) . However, the role of these downstream effects of EGFR transactivation by GPCRs in mediating tumor progression has not been fully elucidated. Our results have several important implications. Both GRPR and EGFR are overexpressed in HNSCC (as well as many other cancers, including NSCLC), which suggests that cross-talk between these two growth factor receptors may represent a common mitogenic signaling pathway. We showed that both GRP/GRPR and EGFR autocrine pathways coexist and interact to stimulate cell proliferation in HNSCC.
Therefore, abrogation of one autocrine regulatory pathway may modulate the other autocrine pathway. EGFR activity appears to be critical for transmitting the mitogenic signals of GRP in HNSCC, and suggests that this GPCR mitogenic pathway could be blocked effectively by EGFR inhibition. If all of the GRPinduced effects on tumor growth require EGFR activation, EGFR blockade may prove to be an effective therapeutic strategy for GRP/GRPR-overexpressing tumors. In fact, encouraging results have been reported from Phase I clinical trials of EGFR targeting therapies in HNSCC patients (Shin et al., 2001) . Clinical responses have also been observed in lung cancer patients treated with a GRP neutralizing antibody (Kelley, 1997) . If GRP induces both EGFR-dependent and EGFR-independent signals for tumor progression, combination therapy targeting both GRP/GRPR and EGFR pathways may prove complementary and synergistic. The potential involvement of other receptor tyrosine kinases in relaying GRPR signaling may represent a new mechanism for tumor development.
Materials and methods
Chemicals and reagents
Human GRP was obtained from Sigma-Aldrich Corporation (St Louis, MO, USA). Human recombinant EGF was obtained from Oncogene Research Products (Boston, MA, USA). HGF was purchased from Calbiochem (San Diego, CA, USA). Antibodies against EGFR were obtained from the Transduction Laboratories (Lexington, KY, USA) and Upstate Biotechnology (Lake Placid, NY, USA). Antibodies against p44/42-MAPK and phosphorylated p4/42-MAPK were obtained from New England Biolabs (Beverly, MA, USA). Specific EGFR tyrosine kinase inhibitors, PD153035 and tyrphostin AG-1478 and AG-9 (a control compound for AG-1478) were obtained from Calbiochem-Novabiochem Corporation (San Diego, CA, USA). CRM197 was purchased from List Biological Laboratories (Campbell, CA, USA). The MEK inhibitor (U0126) was purchased from Cell Signaling Technologies (Beverly, MA, USA). The anti-HB-EGF and anti-TGF-a neutralizing antibodies were obtained from Oncogene research products (San Diego, CA, USA). The EGFR blocking antibody M225 was obtained from Imclone Systems Incorporated (New York, NY, USA). Matrix metalloproteinase inhibitors Marimastat and GM6001 were obtained from British Biotech (Oxford, England) and Calbiochem-Novabiochem Corporation (San Diego, CA, USA), respectively. The TGF-a ELISA kit was purchased from Oncogene research products (San Diego, CA, USA).
Cell culture
All head and neck squamous cell carcinoma cell lines (1483, UM-22B, UPCI:SCC-103 and PCI-15b) were of human origin. The UPCI:SCC-103 cell line was a kind gift from Dr S Gollin (University of Pittsburgh, PA, USA). Cells were maintained in DMEM with 12% heat-inactivated fetal calf serum (Invitrogen, Carlsbad, CA, USA) at 371C with 5% CO 2 . Primary cultures were generated from murine embryonic fibroblasts derived from EGFR knockout mice (Jackson Laboratories), and their corresponding wild-type littermates (CD1 background) obtained at age E 16.5 days. Genotypying was determined using the appropriate primers. Following genotyping, tissues were harvested and cultures generated by mincing organs and incubating in trypsin-EDTA (Invitrogen Corporation, Carlsbad, CA, USA) for 15 in at 371C followed by centrifugation and resuspension in cell dissociation solution (Sigma-Aldrich Corporation, St Louis, MO, USA) for 40 min at 371C, and then plating in Petridishes pretreated with 0.05 mg/ml collagen in 0.2 n acetic acid. The medium was changed twice a week and cells were trypsinized every 7-14 days and passaged. Primary cell cultures were maintained in DMEM containing 20% heat-inactivated fetal calf serum at 371C with 5% CO 2 .
Proliferation assays
Cells were plated at low density (2.5 Â 10 4 cells) and allowed to seed overnight in a 24-well plate. Cells were then treated with different concentrations of GRP (5-400 nm) or the control vehicle (water) in serum-free DMEM. After 3 days, cells were harvested and cell number was determined by counting. When the proliferation study was performed in the presence of inhibitors (e.g. PD153035, AG-1478, AG-9 and U0126, or with the solvent control, DMSO), GRP and inhibitors were added at the same time. Statistical analysis (unpaired t-test) was performed using GraphPad Prism Software (GraphPad Software, San Diego, CA, USA).
Cell treatments
HNSCC cells 1483 (2 Â 10 5 cells/ml) were plated in 10 cm 2 plates. At 24 h after plating, cells were serum-starved for 72 h in serum-free DMEM. During serum starvation the medium was changed every 24 h. For UM-22B and UPCI:SCC103 cells, 2 Â 10 5 cells were plated in 10 cm 2 plates. For the experiments with inhibitors, cells were pretreated with either 6 mg/ml of M225, 1 mg/ml of CRM197, 20 mm Marimastat, 20 nm GM6001, 200 nm PD153035, 250 nm AG-9 or 250 nm AG-1478. For experiments involving TGF-a neutralizing antibody, cells were treated with 7 mg/ml antibody during the last 24 h of serum starvation. Control wells were treated with vehicle (water) or DMSO for 2 h before the addition of growth factors. After pretreatment, where required, 400 nm GRP or 10 ng/ml EGF was added to the cells. At selected time points after growth factor stimulation, cells were washed 3 times with cold PBS, lysed with lysis buffer (10 mm Tris-HCl, pH 7.6, 50 mm Na 4 P 2 O 7, 50 mm NaF, 1 mm NaV 3 O 4 , 1% Triton Â -100 and 1 Â protease inhibitor cocktail tablet that included a broad spectrum potent inhibitor of protein tyrosine phosphatases (Roche, Germany), scraped off the plate, and passed through a 26 1=2 gauge needle 3-4 times. The lysate was then centrifuged at 41C, 14 000 r.p.m. for 5 min. Supernatant was collected for protein quantitation. Protein quantitation was performed using the Protein Assay Solution (BioRad Laboratories, Hercules, CA, USA) and bovine serum albumin of known concentration as the standard.
Immunoprecipitation of phosphorylated EGFR
In total, 100 mg of total protein was incubated for 2 h at 41C with 3 mg of anti-EGFR antibody (Upstate Biotechnology, Lake Placid, NY, USA) with gentle agitation. In total, 40 ml of Protein agarose G beads (Invitrogen, Carlsbad, CA, USA) were added to the lysate and incubated overnight at 41C with gentle agitation. The beads were collected by centrifugation at 41C, 14 000 r.p.m. for 1 min. The beads were resuspended and washed with lysis buffer 3 times. The beads were resuspended in 20 ml of 2 Â loading dye and boiled for 5 min at 951C. The immunoprecipitated proteins were then resolved on an 8% SDS-PAGE gel. After being transferred onto a Protran membrane, the membrane was blocked in 5% milk and blotted with the antiphosphotyrosine antibody PY99 (Santa Cruz Biotechnology, CA, USA) at 1:1000 in Blotto solution (0.6% dry milk powder, 0.9% NaCl, 0.5% Tween 20 and 50 mm Tris, pH 7.4). The immunoblot was then developed using the Luminol Reagent (Santa Cruz Biotechnology, CA, USA) and subjected to autoradiography. Blots were stripped in 0.1 m glycine, pH 2.9 for 2 h at room temperature, blocked for 1 h and reprobed with EGFR antibody (Transduction Laboratories, Lexington, KY, USA) at 1:1000 in blotto solution for 2 h.
Western blotting
In total, 30 mg of protein was resolved in an 8% SDS-PAGE gel and transferred onto a Protran membrane (Schleicher & Schuell Inc., Keene, NH, USA) using a semi-dry transfer machine (BioRad Laboratories, Hercules, CA, USA). After protein transfer, the membrane was blocked overnight with a blocking solution containing 5% nonfat dry milk, 0.2% Tween 20 in 1 Â PBS. The membrane was incubated with the primary antibody (1:1000 phospho-p44/42-MAPK or p44/42-MAPK) for 2 h and then washed with the Blotto solution (0.6% dry milk powder, 0.9% NaCl, 0.5% Tween 20 and 50 mm Tris, pH 7.4) 3 times for 10 min. The membrane was then incubated with the secondary antibody (Goat anti-rabbit IgG-HRP conjugate, Bio-Rad Laboratories, Hercules, CA, USA) for 1 h and washed for 10 min (3 times). The membrane was quickly rinsed with a rinsing solution and the blot was developed using Luminol Reagent (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) by autoradiography.
TGF-a ELISA assay
HNSCC cells 1483 (2 Â 10 5 cells/ml) were plated in 10 cm 2 plates. At 24 h after plating, cells were serum-starved for 72 h in serum-free DMEM. During serum starvation the medium was changed every 24 h. Cells were pretreated with 20 mm Marimastat for 2 h at 371C with 5% CO 2 to block MMPs. Cells were treated with 400 nm GRP for 10 min. Supernatants were collected and cells were subjected to centrifugation at 1300 r.p.m. for 10 min. Pellets were discarded and the supernatant was tested for levels of TGF-a by ELISA as per the manufacturer's instructions.
